An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Risdiplam (RO7034067) in Adult and Pediatric patients with Spinal Muscular Atrophy - BP39054

F. Hoffmann-La Roche AG0 个研究点目标入组 167 人开始时间: 2023年10月24日最近更新: 2024年8月21日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: F. Hoffmann-La Roche AG
入组人数: 167

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 64（—）
性别: All

入选标准

•1. Males and females 6 months to 60 years of age inclusive (at screening), 2. Confirmed diagnosis of 5q-autosomal recessive SMA, 3. Previous enrollment in Study BP29420 (Moonfish) with the splicing modifier RO6885247 or previous treatment with nusinersen (defined as having received = 4 doses of nusinersen, provided that the last dose was received = 90 days prior to screening),olesoxime (provided that the last dose was received = 18 months and = 90 days prior to screening) or onasemnogene abeparvovec (AVXS-101) (provided that the time of treatment was = 12 months prior to screening), 4. Adequately recovered from any acute illness at the time of screening and considered well enough to participate in the opinion of the Investigator, 5. For patients aged 2 years or younger at screening: •Receiving adequate nutrition and hydration (with or without gastrostomy) at the time of screening, in the opinion of the Investigator •Medical care meets local accepted standard of care, in the opinion of the Investigator •Would be able to complete all study procedures, measurements and visits, and the parent or caregiver of the patient has adequately supportive psychosocial circumstances, in the opinion of the Investigator •Parent or caregiver of patient is willing to consider nasogastric, nasojejunal or gastrostomy tube placement, as recommended by the Investigator, during the study to maintain safe hydration, nutrition and treatment delivery •Parent or caregiver of patient is willing to consider the use of noninvasive ventilation, as recommended by the Investigator during the study

排除标准

•1. With the exception of studies of olesoxime, AVXS-101, or nusinersen: Previous participation in any investigational drug or device study within 90 days prior to screening, or 5 half-lives of the drug, whichever is longer, 2. Any history of gene or cell therapy, with the exception of AVXS-101, 3. Unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system diseases as considered to be clinically significant by the Investigator, 4. Inadequate venous or capillary blood access for the study procedures, in the opinion of the Investigator, 5. For patients aged <2 years, hospitalization for a pulmonary event within 2months prior to screening and pulmonary function not fully recovered at the time of screening, 6. Lactating women

研究者

发起方

F. Hoffmann-La Roche AG

相似试验

进行中（未招募）

1 期

A study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Risdiplam in adult and pediatric patients with spinal muscular atrophySpinal Muscular Atrophy (SMA)MedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2016-004184-39-DEF. Hoffmann-La Roche Ltd180

进行中（未招募）

1 期

EUCTR2016-004184-39-BEF. Hoffmann-La Roche Ltd180

进行中（未招募）

1 期

EUCTR2016-004184-39-GBF. Hoffmann-La Roche Ltd180

进行中（未招募）

1 期

A study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Risdiplam (RO7034067) in adult and pediatric patients with spinal muscular atrophySpinal Muscular Atrophy (SMA)MedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2016-004184-39-NLF. Hoffmann-La Roche Ltd180

进行中（未招募）

1 期

A study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of RO7034067 in adult and pediatric patients with spinal muscular atrophy

EUCTR2016-004184-39-PLF. Hoffmann-La Roche Ltd180